NetworkNewsBreaks

TuesdayMar 10, 2026 11:39 am

NetworkNewsBreaks – AST SpaceMobile, Inc. (NASDAQ: ASTS) Prices $1.0 Billion Convertible Senior Notes Offering Due 2036

AST SpaceMobile (NASDAQ: ASTS) announced the pricing of $1.0 billion aggregate principal amount of 2.250% convertible senior notes due 2036 in a private offering to qualified institutional buyers under Rule 144A of the Securities Act of 1933. The notes carry an initial conversion price of approximately $116.30 per share, representing a roughly 20% premium to the company’s Feb. 11, 2026 closing price, and the offering is expected to close Feb. 17, 2026, subject to customary conditions. AST SpaceMobile also granted initial purchasers an option to buy up to an additional $150 million of notes, with proceeds expected to support global spectrum deployment, technology commercialization including artificial intelligence opportunities, government space initiatives, debt reduction and other general corporate purposes. To view the…

Continue Reading

TuesdayMar 10, 2026 10:49 am

NetworkNewsBreaks – Lahontan Gold Corp. (TSX.V: LG) (OTCQB: LGCXF) Appoints Two Independent Directors to Board 

This article has been disseminated on behalf of Lahontan Gold Corp. and may include paid advertising.  Lahontan Gold (TSX.V: LG) (OTCQB: LGCXF) announced the appointment of Antony Rowe and Miranda Werstiuk as independent directors to the company’s board of directors. In conjunction with the appointments, Josh Serfass and Max Pluss have stepped down from the board. The leadership update comes as the company advances its business strategy and progresses the Santa Fe Mine project toward gold and silver production, with management noting that the refreshed board brings experience in mine development and mining finance to help guide Lahontan through its transition from mine developer to mine builder. To…

Continue Reading

TuesdayMar 10, 2026 10:20 am

NetworkNewsBreaks – Oragenics Inc. (NYSE American: OGEN) Receives Australian Ethics Approval to Launch Phase IIa Concussion Trial

Oragenics (NYSE American: OGEN) announced it has received final Human Research Ethics Committee approval in Australia to begin its Phase IIa clinical trial evaluating ONP-002, its lead intranasal neurosteroid drug candidate for the treatment of concussion, also known as mild traumatic brain injury. With all regulatory approvals secured, the company has initiated clinical site onboarding at three locations in Australia, led by Bayside Health (Alfred Health), and expects to dose the first patient before the end of March. The randomized, placebo-controlled study will enroll 40 patients to evaluate safety, tolerability and feasibility of ONP-002, with data expected before year-end 2026 as the company prepares for a future investigational new drug…

Continue Reading

TuesdayMar 10, 2026 9:12 am

NetworkNewsBreaks – Frontieras North America to Host Groundbreaking for West Virginia Commercial Facility

Frontieras North America, an energy and environmental technology company commercializing its patented FASForm(TM) Solid Carbon Fractionation process, announced it will host a groundbreaking ceremony on April 2, 2026, for its first commercial facility in Mason County, West Virginia. The estimated $850 million industrial project is expected to create approximately 300 full-time jobs with wages averaging three times the area’s average income, along with about 2,000 construction jobs during the build phase. The ceremony, scheduled for 11:30 a.m. ET, will include remarks from company leadership and federal and state officials, followed by a ceremonial groundbreaking. The company’s FASForm(TM) technology is designed to convert coal…

Continue Reading

TuesdayMar 10, 2026 9:10 am

NetworkNewsBreaks – Nevada Organic Phosphate Inc. (CSE: NOP; OTCQB: NOPFF) Mobilizes Teams to Murdock Mountain for 2026 Field Season

This article has been disseminated on behalf of Nevada Organic Phosphate Inc. and may include paid advertising. Nevada Organic Phosphate (CSE: NOP; OTCQB: NOPFF) announced that its environmental consultants and exploration team have mobilized to the Murdock Mountain Property, marking the official start of the company’s 2026 field season. Following several weeks of weather delays, crews have begun environmental baseline work, access inspections and field preparations to support an upcoming drill program, with drilling expected to begin soon as ground conditions continue to stabilize. In addition to advancing the core project, the company will begin exploring three additional lease applications…

Continue Reading

TuesdayMar 10, 2026 9:00 am

NetworkNewsBreaks – Uranium Energy Corp. (NYSE American: UEC) Files Quarterly Report for Quarter Ended Jan. 31, 2026

Uranium Energy (NYSE American: UEC) announced that it has filed its Quarterly Report on Form 10-Q for the quarter ended Jan. 31, 2026, highlighting progress across its U.S. in-situ recovery (“ISR”) uranium operations and balance sheet strength. During the quarter, the company completed construction of the Burke Hollow ISR uranium mine, expanded production capacity in Wyoming and South Texas pending final regulatory approvals and advanced feasibility, siting and licensing work for United States Uranium Refining & Conversion Corp. UEC also reported selling uranium at prices more than 25% above the quarterly average while maintaining $818 million in liquid assets and no…

Continue Reading

TuesdayMar 10, 2026 9:00 am

NetworkNewsBreaks – MAX Power Mining Corp. (CSE: MAXX; OTC: MAXXF; FRANKFURT: 89N) Adopts Shareholder Rights Plan

This article has been disseminated on behalf of MAX Power Mining and may include paid advertising.  MAX Power Mining (CSE: MAXX; OTC: MAXXF; FRANKFURT: 89N) has adopted a Shareholder Rights Plan and entered into a Shareholder Rights Plan Agreement with TMX Trust Company as rights agent, effective immediately. The plan, which is consistent with similar measures adopted by Canadian public companies and was not implemented in response to any specific takeover proposal, is designed to provide the company’s board and shareholders adequate time to evaluate any unsolicited takeover bid, explore value-enhancing alternatives and ensure shareholders receive full and fair value. The plan will be subject to…

Continue Reading

TuesdayMar 10, 2026 9:00 am

NetworkNewsBreaks – Soligenix Inc. (NASDAQ: SNGX) SGX945 Granted Promising Innovative Medicine Designation in UK for Behçet Disease

Soligenix (NASDAQ: SNGX) announced that SGX945 (dusquetide) has received Promising Innovative Medicine (“PIM”) designation from the U.K. Medicines and Healthcare Products Regulatory Agency for the treatment of Behçet’s Disease. The designation represents the first step toward potential inclusion in the U.K.’s Early Access to Medicines Scheme, which allows patients with life-threatening or seriously debilitating conditions to access promising therapies earlier. The PIM designation was granted based on Phase 2 clinical data indicating that dusquetide may provide a significant advantage over existing treatments while demonstrating a favorable potential benefit-risk profile for patients with this rare inflammatory disorder. To view the full…

Continue Reading

TuesdayMar 10, 2026 9:00 am

NetworkNewsBreaks – McEwen Inc. (NYSE: MUX) (TSX: MUX) Announces Q4 and Year-End 2025 Conference Call Scheduled for March 12

This article has been disseminated on behalf of McEwen Inc. and may include paid advertising.  McEwen (NYSE: MUX) (TSX: MUX) has invited investors to join its fourth quarter and year-end 2025 conference call scheduled for Thursday, March 12, 2026, at 3:00 p.m. EDT. During the call, management will discuss the company’s financial results and project developments, followed by a question-and-answer session in which participants will be able to submit questions directly by phone during the webcast.  To view the full press release, visit, https://nnw.fm/tOjJR About McEwen  McEwen shares trade on both the NYSE and TSXunder the ticker MUX.  McEwen provides its shareholders with exposure to a growing base of gold and silverproduction in addition…

Continue Reading

MondayMar 09, 2026 9:55 am

NetworkNewsBreaks – Octane Announces Neuro Tech Forum 2026 to Be Held March 26-27 in Newport Beach

Octane announced that the Octane Neuro Tech Forum 2026 will take place March 26-27, 2026, at VEA Newport Beach, A Marriott Resort & Spa in Newport Beach, California, bringing together industry leaders, clinicians, investors and entrepreneurs to advance innovation in neurotechnology. The event, part of Octane’s Innovation Event Series, will feature keynote speaker Dr. Adnan Siddiqui, CEO and CMO of the Jacobs Institute, along with more than 30 expert speakers addressing emerging neurotech technologies, digital health innovation, brain-computer interfaces and the evolving investment landscape. The forum will include innovation panels, investor-focused sessions, company presentations and networking opportunities designed to foster…

Continue Reading